Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial

Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial

Abstract Background The antimetabolites methotrexate (MTX) and mycophenolate mofetil (MMF) are commonly used as initial corticosteroid-sparing treatment for uveitis. There is little data examining risk factors for failing both MTX and MMF. The objective of this study is to determine risk factors for...

Full description

Bibliographic Details
Main Authors: Amit K. Reddy, D. Claire Miller, Amol A. Sura, SR Rathinam, John A Gonzales, Radhika Thundikandy, Anuradha Kanakath, Bala Murugan, Rajesh Vedhanayaki, Lyndell L. Lim, Eric B. Suhler, Thuy Doan, Hassan A. Al-Dhibi, Debra A. Goldstein, Lourdes Arellanes-Garcia, Nisha R Acharya
Format: Article
Language:English
Published: SpringerOpen 2023-06-01
Series:Journal of Ophthalmic Inflammation and Infection
Subjects:
Non-infectious uveitis
Immunomodulatory therapy
Methotrexate
Mycophenolate mofetil
Retinal vasculitis
Online Access:https://doi.org/10.1186/s12348-023-00350-5

Internet

https://doi.org/10.1186/s12348-023-00350-5

Similar Items